Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2000

View Archived Issues

Potent and selective octapeptide sst3 receptor antagonist identified by Swiss, U.S. researchers

Myogen and BASF to codevelop BSF-208075

Zonagen and Wyeth-Ayerst sign human contraceptive vaccine agreement

Oxford GlycoSciences and Pfizer enter biomarker discovery alliance

AstraZeneca continues to make progress across development portfolio

SLIL designs conformationally restricted polyamine analogues for cancer therapy

AstraZeneca seeks FDA approval for pediatric indication of Naropin

EU recommends approval of PegIntron/Rebetol combination for hepatitis C treatment

CeNeS grants license to Shire for dopamine D1 agonist program

Japanese launch of maxacalcitol announced

Inflazyme's novel asthma therapy enters phase II following U.K. approval

R.W. Johnson delays North American phase III trial of influenza inhibitor

Starlix approved by FDA for treatment of type 2 diabetes

Actis for erectile dysfunction approved by FDA for OTC marketing

Once-daily Detrol approved by FDA for treatment of overactive bladder

Novel method for treating autoimmune diseases revealed by UAB Research Foundation

Sumitomo discloses thiourea derivatives with ECE-inhibitory activity

Sumitomo reports quinazoline derivatives with potential for allergic disease treatment

Novel steroid compounds demonstrate anticancer potential

Tanabe Seiyaku claims isoquinoline derivatives with cardiovascular activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...